AU:NTI Stock Latest News
Company AnnouncementsNeurotech International Reports Change in Director’s Share Interests2d agoNTI
Company AnnouncementsNeurotech International Reports Director Departure and Shareholding1w agoNTI
Company AnnouncementsNeurotech Shareholders Back AGM Resolutions1w agoNTI
Company AnnouncementsNeurotech advances autism drug NTI164 with Phase 3 trial, FDA IND and new funding2w agoNTI
Company AnnouncementsNeurotech Flags High Risks as It Pursues Neurodevelopmental Disorder Therapies3w agoNTI
Company AnnouncementsNeurotech Director Andrew Chapman Boosts Equity Stake1M agoNTICompany AnnouncementsNeurotech International Sets November AGM, Moves to Digital Meeting Materials1M agoNTI
Company AnnouncementsNeurotech’s NTI164 Autism Trial Enters Phase III: What Investors Should Watch1M agoNTI- Company AnnouncementsNeurotech Starts Pivotal Phase 3 Trial of NTI164 for Autism1M agoNTI
Company AnnouncementsNTI164 Rett Trial Moves Toward Phase II/III: What Investors Should Watch2M agoNTI
Company AnnouncementsNeurotech International Adds Major Shareholder Andrew Chapman to Board2M agoNTI
Company AnnouncementsNeurotech International Options Lapse Simplifies Capital Structure2M agoNTICompany AnnouncementsNeurotech Discloses Final Director Interest as Anthony Filippis Steps Down2M agoNTI
Company AnnouncementsNeurotech Narrows Loss as R&D Grants Drive Revenue Surge2M agoNTI- Company AnnouncementsNeurotech Elevates Mark Davies to Executive Chairman as Phase III Cannabinoid Program Advances2M agoNTI
Company AnnouncementsNeurotech Confirms Compliance as New Shares Enter Secondary Trading3M agoNTI
Company AnnouncementsNeurotech International Seeks ASX Quotation for 293 Million New Shares3M agoNTI
Company AnnouncementsNeurotech raises $4.5m to fund pivotal ASD Phase III trial3M agoNTICompany AnnouncementsNeurotech secures FDA IND nod and U.S. patent wins as autism drug program advances3M agoNTI
Company AnnouncementsNeurotech Autism Trial Data Secures Publication in Leading Neurotherapeutics Journal3M agoNTI
